Podcast: This Week in Managed Care—FDA Committee Discuss EUA for J&J Vaccine and Other Health News

February 28, 2021

News

Podcast

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included an FDA committee meeting on J&J's COVID-19 vaccine; cemiplimab approved for first-line advanced non–small cell lung cancer with PD-L1 expression; real-world outcomes contrast cancer clinical trial results in Medicare patients.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Read more about the stories in this podcast:

What We’re Reading: J&J Vaccine Will Go Before FDA; Cancer Survivor Concerns; Wasted COVID-19 Vaccine Doses

What We're Reading: COVID-19 Relief Bill Update; FDA Expedites Trial Process; Hospitalization Risk Reduced

What We're Reading: Pfizer Vaccine Lessens Hospitalization, Death Risk; 6M Doses Delayed; Mental Health in Coronavirus Survivors

FDA Approves Cemiplimab for First-Line Advanced NSCLC With PD-L1 Expression

Real-World Outcomes Contrast Cancer Clinical Trial Results in Medicare Patients

Outcomes Disparities Persist for Black Individuals Living With HIV

Related Content

Modern Medical Technologies - Prostock-studio - stock.adobe.com

The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine

January 29th 2026

Article

Better integration of pharma and medical technology is necessary to enhance patient outcomes and drive value-based care.

The Orphan Drug Act in the Modern Drug Pricing Era

February 3rd 2026

Podcast

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

January 26th 2026

Article

Skilled nursing facilities (SNFs) with a high volume of referred patients with Alzheimer disease and related dementias may work harder to manage care transitions with less availability of resources that enable high-quality handoffs.